A detailed history of Daiwa Securities Group Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 11,798 shares of NBIX stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,798
Previous 8,801 34.05%
Holding current value
$1.41 Million
Previous $1.21 Million 12.21%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $343,396 - $458,990
2,997 Added 34.05%
11,798 $1.36 Million
Q2 2024

Aug 07, 2024

BUY
$130.86 - $143.19 $27,611 - $30,213
211 Added 2.46%
8,801 $1.21 Million
Q1 2024

May 02, 2024

BUY
$130.4 - $143.74 $275,013 - $303,147
2,109 Added 32.54%
8,590 $1.19 Million
Q4 2023

Jan 31, 2024

BUY
$106.07 - $132.76 $47,837 - $59,874
451 Added 7.48%
6,481 $854,000
Q2 2023

Jul 31, 2023

BUY
$89.53 - $104.87 $23,635 - $27,685
264 Added 4.58%
6,030 $569,000
Q1 2023

May 02, 2023

BUY
$94.11 - $123.02 $18,822 - $24,604
200 Added 3.59%
5,766 $584,000
Q4 2022

Feb 06, 2023

SELL
$106.72 - $127.06 $330,084 - $392,996
-3,093 Reduced 35.72%
5,566 $665,000
Q3 2022

Nov 02, 2022

SELL
$92.03 - $107.81 $8,282 - $9,702
-90 Reduced 1.03%
8,659 $920,000
Q2 2022

Aug 09, 2022

SELL
$75.79 - $100.07 $116,716 - $154,107
-1,540 Reduced 14.97%
8,749 $853,000
Q1 2022

Apr 29, 2022

SELL
$72.45 - $94.81 $2,970 - $3,887
-41 Reduced 0.4%
10,289 $964,000
Q4 2021

Feb 03, 2022

SELL
$79.65 - $106.22 $38,789 - $51,729
-487 Reduced 4.5%
10,330 $880,000
Q3 2021

Nov 05, 2021

BUY
$86.18 - $99.03 $14,995 - $17,231
174 Added 1.63%
10,817 $1.04 Million
Q2 2021

Aug 06, 2021

SELL
$89.43 - $102.27 $20,211 - $23,113
-226 Reduced 2.08%
10,643 $1.04 Million
Q1 2021

May 03, 2021

SELL
$87.57 - $119.4 $16,288 - $22,208
-186 Reduced 1.68%
10,869 $1.06 Million
Q4 2020

Feb 04, 2021

BUY
$86.91 - $108.33 $198,850 - $247,859
2,288 Added 26.1%
11,055 $1.06 Million
Q3 2020

Nov 02, 2020

SELL
$96.16 - $135.15 $518,494 - $728,728
-5,392 Reduced 38.08%
8,767 $843,000
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $115,894 - $175,531
-1,543 Reduced 9.83%
14,159 $1.23 Million
Q4 2019

Jan 31, 2020

SELL
$86.8 - $118.57 $504,047 - $688,535
-5,807 Reduced 27.0%
15,702 $1.69 Million
Q3 2019

Nov 04, 2019

SELL
$83.82 - $101.5 $185,158 - $224,213
-2,209 Reduced 9.31%
21,509 $1.94 Million
Q2 2019

Jul 24, 2019

SELL
$72.24 - $91.27 $277,473 - $350,568
-3,841 Reduced 13.94%
23,718 $2 Million
Q1 2019

Apr 26, 2019

SELL
$69.31 - $91.53 $412,671 - $544,969
-5,954 Reduced 17.77%
27,559 $2.43 Million
Q4 2018

Feb 05, 2019

SELL
$68.32 - $124.36 $183,302 - $333,657
-2,683 Reduced 7.41%
33,513 $2.39 Million
Q3 2018

Nov 01, 2018

SELL
$98.88 - $125.85 $1.29 Million - $1.65 Million
-13,083 Reduced 26.55%
36,196 $4.45 Million
Q2 2018

Jul 30, 2018

SELL
$75.3 - $105.99 $1.06 Million - $1.5 Million
-14,108 Reduced 22.26%
49,279 $4.84 Million
Q1 2018

May 02, 2018

BUY
$75.88 - $92.43 $87,186 - $106,202
1,149 Added 1.85%
63,387 $5.26 Million
Q4 2017

Feb 06, 2018

BUY
$58.53 - $77.59 $3.64 Million - $4.83 Million
62,238
62,238 $4.83 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.4B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.